Clinicopathological and Prognostic Significance of C/EBP Homologous Protein (CHOP) in Advanced Gastric Cancer

Xiangwen Zhang,Tingting Zhou,Wenbin Li,Taotao Zhang,Ninwei Che,Guo Zu
DOI: https://doi.org/10.1016/j.prp.2018.06.005
2018-01-01
Abstract:Background: Few studies have reported the clinical and prognostic significance of C/EBP homologous protein (CHOP) in advanced gastric cancer (GC). Therefore, the present study investigated the expression of CHOP in advanced GC patients to determine its potential prognostic role. Methods: The levels of CHOP in 95 patients with advanced GC and adjacent non-cancerous tissues were evaluated by qRT-PCR, western blot and immunohistochemistry. Furthermore, the association of CHOP expression with clinicopathological parameters and prognosis of advanced GC patients was analyzed. Results: The levels of CHOP were down-regulated in advanced GC compared with non-cancerous tissues (P < 0.01). In addition, high CHOP expression more frequently occurred in advanced GC tissues with depth of invasion of T1-2 (P < 0.01), lower clinical stage (TNM I-II stage) (P < 0.05) and without lymph node metastasis (P < 0.05). No significant difference was observed between the expression of CHOP and age, gender, tumor size, lesion site and differentiation (P > 0.05). The Kaplan-Meier survival analyses showed that the overall survival rate of advanced GC patients with positive CHOP expression was significantly higher than that of patients with negative CHOP expression (P < 0.01). Univariate and multivariate Cox proportional hazards models revealed that low CHOP expression (OR = 0.314, 95%CI: 0.176 similar to 0.794, P = 0.003) was an independent factor for poor overall survival in advanced GC patients. Conclusion: Low expression of CHOP predicts the poor prognosis of advanced GC patients, and CHOP may be a prognostic biomarker for patients with advanced GC.
What problem does this paper attempt to address?